Bayer AG
Abrir
SetorFinanças
36.25 0.22
Visão Geral
Variação de preço das ações
24h
Mín
36.05
Máximo
36.64
Rendimento | 6.5B 2.8B |
|---|---|
Vendas | 2B 13B |
EPS | 2.812 |
Rendimento de Dividendos | 0.3 |
Margem de lucro | 20.612 |
Funcionários | 87,757 |
EBITDA | 2.3B 4.4B |
Recomendações | Comprar |
|---|---|
Previsão para 12 meses | +36.09% upside |
Rendimento de Dividendos Médio do Setor | 0.30% 4.69% |
|---|---|
Próximos Ganhos | 4 de ago. de 2026 |
Capitalização de Mercado | -1.4B 35B |
|---|---|
Abertura anterior | 36.03 |
Fecho anterior | 36.25 |
Sentimento de Notícias
By Acuity
60%
40%
373 / 439 Ranking em Finance
Bayer AG Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.